Open Access

Attenuation of hepatic ischemia‑reperfusion injury by adipose stem cell‑derived exosome treatment via ERK1/2 and GSK‑3β signaling pathways

  • Authors:
    • Yaqing Zhang
    • Yonghua Li
    • Qilong Wang
    • Dongyu Zheng
    • Xue Feng
    • Wei Zhao
    • Linlin Cai
    • Qingqing Zhang
    • Haitao Xu
    • Hailong Fu
  • View Affiliations

  • Published online on: December 3, 2021     https://doi.org/10.3892/ijmm.2021.5068
  • Article Number: 13
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Exosomes are an emerging therapeutic tool for the treatment of tissue injuries. In the present study, the protective effect of isolated exosomes from adipose‑derived stem cells (ADSCs‑exo) against hepatic ischemia‑reperfusion (I/R) injury was explored. Hepatic I/R injury was achieved by inducing ischemia for 60 min followed by reperfusion for 2 and 6 h. Pre‑treatment with ADSCs‑exo revealed a significant reduction in necrosis and apoptosis in liver tissue induced by I/R injury. Hypoxic oxidative stress was managed by exosome‑mediated reduced reactive oxygen species and increased superoxide dismutase that in turn protected mitochondrial damage and apoptosis. Reduction in inflammatory mediators such as IL‑1β and TNF‑α was also observed and protection of hepatocytes from I/R injury was evidenced by a significant decrease in biochemical markers of liver damage (alanine transaminase, aspartate transaminase and lactate dehydrogenase). Exosomal prostaglandin E2 (PGE2)‑mediated ERK1/2 and GSK‑3β phosphorylation were revealed to increase Bcl‑2 and decrease Bax expression with mitochondrial permeability transition pore‑inhibition which may be considered a prime mechanism of exosome‑mediated hepatoprotection. In conclusion, our results indicated that ADSCs‑exo pre‑treatment is effective in protecting liver I/R injury.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 49 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Li Y, Wang Q, Zheng D, Feng X, Zhao W, Cai L, Zhang Q, Xu H, Fu H, Fu H, et al: Attenuation of hepatic ischemia‑reperfusion injury by adipose stem cell‑derived exosome treatment via ERK1/2 and GSK‑3β signaling pathways. Int J Mol Med 49: 13, 2022
APA
Zhang, Y., Li, Y., Wang, Q., Zheng, D., Feng, X., Zhao, W. ... Fu, H. (2022). Attenuation of hepatic ischemia‑reperfusion injury by adipose stem cell‑derived exosome treatment via ERK1/2 and GSK‑3β signaling pathways. International Journal of Molecular Medicine, 49, 13. https://doi.org/10.3892/ijmm.2021.5068
MLA
Zhang, Y., Li, Y., Wang, Q., Zheng, D., Feng, X., Zhao, W., Cai, L., Zhang, Q., Xu, H., Fu, H."Attenuation of hepatic ischemia‑reperfusion injury by adipose stem cell‑derived exosome treatment via ERK1/2 and GSK‑3β signaling pathways". International Journal of Molecular Medicine 49.2 (2022): 13.
Chicago
Zhang, Y., Li, Y., Wang, Q., Zheng, D., Feng, X., Zhao, W., Cai, L., Zhang, Q., Xu, H., Fu, H."Attenuation of hepatic ischemia‑reperfusion injury by adipose stem cell‑derived exosome treatment via ERK1/2 and GSK‑3β signaling pathways". International Journal of Molecular Medicine 49, no. 2 (2022): 13. https://doi.org/10.3892/ijmm.2021.5068